Journal
CURRENT DRUG TARGETS
Volume 23, Issue 11, Pages 1040-1056Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389450123666220421124030
Keywords
Alzheimer's disease; amyloid beta; clinical research; immunotherapy; and drug development; neurodegenerative disorder
Categories
Funding
- Youth Innovation Team of Shaanxi Universities
Ask authors/readers for more resources
Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory impairment and cognitive decline. Despite the challenges in developing disease-modifying treatments targeting amyloid plaques, recent studies have shown that active immunotherapy against amyloid-beta may have positive effects.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by memory impairment and cognitive decline. The obvious pathological features of AD are still amyloid plaques and neurofibrillary tangles. Development of disease-modifying treatments for AD has been challenging, with almost all drugs aborted. The amyloid cascade concept has been questioned due to the failures of various amyloid-targeting prospects. Despite this, targeting amyloid-beta (A beta) active immunotherapy provided some positive results to support this hypothesis and clinical trials of these candidates are ongoing. In this review, we describe the latest advance in therapeutic strategies based on amyloidogenic processing and evaluate the pros and cons of each treatment strategy. We also highlight the current status of the hottest immunotherapy and discuss the future development direction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available